Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

uTRACT Jelmyto Registry: A Multicenter, Prospective and Retrospective Registry to Evaluate Real World Experience and Outcomes of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto

NCT05874921 is registered in ClinicalTrials.gov with UroGen Pharma Ltd. as lead sponsor.

NCT NCT05874921
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05874921 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
uTRACT Jelmyto Registry: A Multicenter, Prospective and Retrospective Registry to Evaluate Real World Experience and Outcomes of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
Lead sponsor
UroGen Pharma Ltd.
Phase
Observational
Overall status
Recruiting
Start date
November 17, 2023
Completion date
October 31, 2030
Enrollment
450 (estimated)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, transitional cell, transitional cell carcinoma of renal pelvis, urothelial cancer of renal pelvis, urothelial carcinoma, urothelial carcinoma of the renal pelvis and ureter, urothelial carcinoma recurrent, urothelial carcinoma ureter, urothelial carcinoma ureter recurrent